SPY424.31+0.70 0.17%
DIA345.12+0.14 0.04%
IXIC14,069.42+49.09 0.35%

Sonnet Bio's Interleukin 12 Candidate For Solid Tumor Shows Encouraging Action Preclinical Studies

05/10/2021 07:51
  • Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) has a preclinical nonhuman primate GLP repeat-dose study of SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) platform.
  • The FHAB technology targets the tumor and lymphatic tissue, providing a mechanism for dose sparing.
  • The study's objectives were to evaluate the toxicity of SON-1010 in the primates using a subcutaneous, repeat-dose regimen at three different dose levels versus untreated controls and to evaluate the potential reversibility of any adverse findings.
  • The NHP data demonstrates that SON-1010 appears to be safe and is eliciting the expected immune responses.
  • After repeated administration, no observed adverse event level was more than 50 times the anticipated equivalent human clinical dose in NHP, with no evidence of cytokine release syndrome.
  • Pharmacokinetic (PK) analysis of serum samples confirmed an enhanced profile of IL12-FHAB over recombinant human IL-12, with a half-life of around 40 hours in NHP.
  • A significant increase in Interferon-γ, a key pleiotropic cytokine associated with anti-tumor mechanisms, was observed following dosing with IL12-FHAB.
  • By Day 38, all study subjects recovered to baseline (pre-study) values.
  • Repeat dosing administration was tolerated at all dose levels examined.
  • Given that IL12-FHAB has an extended half-life, tolerable doses can be given at longer dosing intervals.
  • The company will provide GMP material for the initiation of the clinical trial in 2H 2021.
  • Price Action: SONN shares are up 5.6% at $1.71 during the premarket session on the last check Monday.